Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Recruiting

Phase 1

Iberdomide & CC-99282Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Sponsor:

Celgene

Code:

NCT04884035

Conditions

Lymphoma, B-Cell

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CC-220

Rituximab

Cyclophosphamide

Doxorubicin

Vincristine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-13. This information was provided to ClinicalTrials.gov by Celgene on 2025-11-05.